Lexaria Bioscience Corp. (NASDAQ: LEXX) Releases Partial Results from Human Clinical Trial of DehydraTECH(TM)-Processed Cannabidiol for Hypertension
Clinical study HYPER-H21-1 evaluates the use of patented DehydraTECH(TM)-processed CBD for use against hypertension Hypertension is a primary or contributing factor in the death of almost 500,000 people per year, with approximately one in four adults aged 20 to 44 suffering from high blood pressure Initial results of the study show that blood pressure was reduced in both male and female volunteers, resulting in the reinforcement of pre-existing findings demonstrating that DehydraTECH delivers superior performance Lexaria plans on launching two additional clinical trials, for a total of three clinical trials in 2021 for the DehydraTECH-CBD with hypertension applications Lexaria (NASDAQ:…